Bevacizumab and Rucaparib in Recurrent Carcinoma of the Cervix or Endometrium

NCT03476798 | Completed Phase 2 Results DMC FDA Drug

• 1 other identifier: OU-SCC-CLOVIS-001
• Study Type: interventional
• Target: 49
• Locations: 1 country
• Sites: 3

Brief Summary

This is a phase II study of rucaparib, a small molecule inhibitor poly (adenosine diphosphate \[ADP\]-ribose) polymerase (PARP), being tested in combination with bevacizumab in patients with recurrent cervical or endometrial cancer. The objective of this study is to determine the proportion of these patients who survive progression-free for at least 6 months while receiving this drug combination.

Conditions

Cervical Cancer; Endometrial Cancer

Outcome Measures

Primary Outcomes (1)

• Proportion of Patients Who Are Progression-free at 6 Months

  To estimate the proportion of pts treated w/bevacizumab who are progression-free. Progression for measurable disease per RECIST v1.1. Progression for pts with non-measurable disease at baseline is defined as increasing clinical, radiological, or histological evidence of disease since study entry.

  6 months

Secondary Outcomes (4)

• Proportion of Patients Who Had Objective Tumor Response

  up to 2 years

• Number of Patients Who Experience Toxicity

  up to 2 year

• Median Overall Survival

  up to 2 years

• Median Progression-free Survival Time

  up to 2 years

Study Arms (1)

Bevacizumab + Rucaparib

EXPERIMENTAL

Drug: Rucaparib; Drug: Bevacizumab

Interventions

Rucaparib DRUG

Rucaparib 600mg PO BID daily

Bevacizumab + Rucaparib

Bevacizumab DRUG

Bevacizumab 15mg/kg IV on day 1 of each cycle

Bevacizumab + Rucaparib

Eligibility Criteria

• Age: 18 Years - 99 Years
• Sex: female
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Patients with histologically-documented carcinoma of the cervix or endometrium.
• Patients with measurable and/or evaluable lesions as defined by RECIST 1.1.
• Women at least 18 years of age
• Patients with persistent or recurrent squamous cell or adenocarcinoma of the cervix, or any carcinoma or carcinosarcoma of the endometrium who has undergone at least one prior line of systemic therapy. Prior bevacizumab is allowed. (Note: previous cisplatin during radiation therapy should NOT count as a prior line of systemic therapy).
• ECOG performance status of 0, 1, or 2.
• Patients should agree to have tumor biopsy for correlative studies.If the patients are unable to be safely biopsied and desire enrollment, they may be enrolled per principal investigator discretion.
• Adequate organ function should be confirmed by the following laboratory values obtained ≤ 14 days prior to first dose of rucaparib.
• Patients must have a life expectancy of at least 3 months ((to be able to complete one cycle of study treatment).
• Patients should have no major existing co-morbidities or medical conditions that will preclude therapy in the view of the principal investigator.
• Prior bevacizumab is allowed if off drug ≥ 28 days prior to study enrollment.
• Women of childbearing potential must not be considering getting pregnant and must avoid pregnancy during the study and for at least six months after the last dose of rucaparib or longer if requested by local authorities.

You may not qualify if:

• Have active second malignancy, i.e., patient known to have potentially fatal cancer present for which she may be (but not necessarily) currently receiving treatment; However patients with a history of malignancy that has been completely treated, with no evidence of that cancer currently, are permitted to enroll in the trial provided all chemotherapy was completed \>6 months prior and/or bone marrow transplant (BMT) \>2 years prior to first dose of rucaparib.
• Prior treatment with any PARP inhibitor.
• Untreated or symptomatic central nervous system (CNS) metastases.Patients with asymptomatic CNS metastases are eligible provided they have been clinically stable for at least 4 weeks.
• Patients who have received treatment with chemotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C); or radiation, biologic/targeted agents, experimental drugs within 3 weeks prior to first dose of rucaparib; and/or ongoing adverse effects from such treatment \> NCI CTCAE Grade 1 (Grade 2 non-hematologic toxicity to most recent treatment may be permitted with prior advanced approval from Sponsor).
• Hospitalization for bowel obstruction within 3 months prior to enrollment.
• Patients must have no history of gross hemoptysis (defined as bright red blood of a ½ teaspoon or more) or coagulopathy. Patients with history of major tumor-related bleeding that is not controlled despite locoregional treatment or at high risk of recurrent tumor-related bleeding will be excluded.
• Patients with history of hypertension must be well-controlled (≤150/100) on a stable regimen of anti-hypertensive therapy.
• Patients with tumors that invaded major vessels (e.g. the carotid) as shown unequivocally by imaging studies will be excluded due to the possibility of increased risk for tumor bleeding with bevacizumab therapy.
• Patients should not have a major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to study enrollment, or anticipation of need for major surgical procedure during the course of the study. No history of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 28 days prior to registration. No serious non-healing wound, ulcer, or bone fracture.
• Patients should not have unstable angina or myocardial infarction within the previous 6 months; no uncontrolled hypertension; no symptomatic congestive heart failure; no serious cardiac arrhythmia requiring medication; no clinically significant peripheral vascular disease; no history of any CNS cerebrovascular ischemia or stroke within the last 6 months; no active serious infection.
• Patients should not have other coexisting medical condition that would preclude full compliance with the study.
• Patients may not be receiving any other investigational agents.
• Patients should not have a history of prior severe infusion reaction to a monoclonal antibody. Patients with known hypersensitivity of Chinese hamster ovary cell products or other recombinant human antibodies.
• Pregnant women are excluded from this study because rucaparib and bevacizumab have the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with rucaparib and bevacizumab, breastfeeding should be discontinued if the mother is treated with rucaparib and bevacizumab. Should a woman become pregnant or suspect she is pregnant while in this study, she should inform her treating physician immediately.
• HIV-positive patients receiving combination anti-retroviral therapy are excluded from the study because of possible drug interactions with rucaparib and bevacizumab.

Sponsors & Collaborators

• University of Oklahoma: lead
• Clovis Oncology, Inc.: collaborator

Study Sites (3)

University of Minnesota

Minneapolis, Minnesota, 55455, United States

Location

Stephenson Cancer Center, University of Oklahoma Health Sciences Center

Oklahoma City, Oklahoma, 73117, United States

Location

University of Virginia Cancer Center

Charlottesville, Virginia, 22903, United States

Location

MeSH Terms

Conditions

Uterine Cervical Neoplasms; Endometrial Neoplasms

Interventions

rucaparib; Bevacizumab

Condition Hierarchy (Ancestors)

Uterine Neoplasms; Genital Neoplasms, Female; Urogenital Neoplasms; Neoplasms by Site; Neoplasms; Uterine Cervical Diseases; Uterine Diseases; Genital Diseases, Female; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Genital Diseases

Intervention Hierarchy (Ancestors)

Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal; Antibodies; Immunoglobulins; Immunoproteins; Blood Proteins; Proteins; Amino Acids, Peptides, and Proteins; Serum Globulins; Globulins

Results Point of Contact

• Title: Dr. Kathleen Moore
• Organization: Stephenson Cancer Center

Kathleen-Moore@ouhsc.edu

405-271-8777

Study Officials

• Kathleen Moore, MD

  Obstetrics and Gynecology

  PRINCIPAL INVESTIGATOR

Publication Agreements

• PI is Sponsor Employee: No
• Restrictive Agreement: No

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: March 19, 2018
• First Posted: March 26, 2018
• Study Start: June 29, 2018
• Primary Completion: May 12, 2020
• Study Completion: September 29, 2023
• Last Updated: February 15, 2024
• Results First Posted: May 28, 2021

Record last verified: 2024-02

Locations

US (3)